Chemexpress(688131) 证券之星· Zheng Quan Zhi Xing·2025-03-27 16:36Core Viewpoint - The report provides an overview of the fundraising activities and the actual usage of funds by Shanghai Haoyuan Pharmaceutical Co., Ltd. for the year 2024, confirming compliance with regulatory requirements and reflecting the company's financial management practices accurately [1][2][3]. Fundraising Overview - The total amount raised through the initial public offering (IPO) was RMB 1,208,814,000, with a net amount of RMB 1,108,194,309.86 after deducting issuance costs [4][6]. - The company issued 1,860,000 shares at a price of RMB 64.99 per share, with the funds fully received by June 3, 2021 [4][5]. - Additional fundraising through the issuance of shares for asset acquisition raised RMB 49,999,961.52, with a net amount of RMB 40,516,942.65 after costs, received by December 30, 2022 [4][5]. Fund Usage and Balance - As of December 31, 2024, all raised funds had been utilized, resulting in a balance of RMB 0.00 in the fundraising account [6][9]. - Cumulative investments in fundraising projects amounted to RMB 1,129,583,127.02, with no remaining balance in the fundraising storage account [6][9]. Fund Management Practices - The company established a fundraising management policy to ensure the proper storage, approval, usage, and supervision of the funds [7][8]. - The company signed tripartite agreements with banks for the management of fundraising accounts, ensuring compliance with regulatory guidelines [7][8]. Investment Project Details - The company reported specific investment amounts for various projects, including RMB 112,958.31 million for the IPO funds and RMB 5,007.79 million for the asset acquisition funds [9][10]. - The company utilized self-raised funds for preliminary investments in projects before the actual fundraising was completed, totaling RMB 104,896,289.07 [10][11]. Cash Management - The company engaged in cash management activities using temporarily idle funds, with a maximum of RMB 30 million allocated for safe, liquid investments [13][14]. - The cash management products included structured deposits and other financial instruments, ensuring the safety and liquidity of the funds [16][17]. Use of Surplus Funds - The company approved the use of surplus funds from completed projects for other fundraising projects, amounting to RMB 1,834.37 million [20][21]. - The company also utilized surplus funds for operational liquidity, with a total of RMB 16,919.43 million used for this purpose [18][19]. Compliance and Reporting - The company confirmed that all fundraising activities and fund usage were disclosed accurately and complied with relevant regulations, with no violations reported [24].